On Monday, July 12, Hyderabad-based pharmaceutical firm Bharat Biotech announced that all documents required for approval of COVID-19 vaccine Covaxin in the emergency use list (EUL) have been submitted to the World Health Organisation (WHO).
The review process is ongoing and the firm is expected to receive authorisation at the earliest, it added.
"All documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to WHO as of July 9. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest," Bharat Biotech International Ltd Chairman and MD Krishna Ella said in a tweet posted by the company.
COVAXIN® EUL pic.twitter.com/dCilH7KbSk
— BharatBiotech (@BharatBiotech) July 12, 2021
The statement came days after WHO chief scientist Soumya Swaminathan said a decision regarding Covaxin’s emergency use listing will be announced within four to six weeks.
Also Read: Covaxin, Covishield or Sputnik V? AIIMS Director Randeep Guleria on which vaccine is most effective
According to reports, the pre-submission meeting between the two sides took place in June in Singapore.
Meanwhile, as per the WHO site, the health body will go through Covaxin's data and publish an anticipated date by when the approval is likely to come. If approved by the WHO, the vaccine, which has thus far received emergency use authorisation (EUA) in 16 countries, is likely to be cleared for use by several other countries.
According to WHO guidelines, EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies.
So far, the WHO has approved vaccines Pfizer-BioNTech, AstraZeneca- SK Bio/SII, Johnson & Johnson Janssen, Moderna, and Sinopharm for emergency use.
Also Read: AIIMS Chief Says Covaxin Will be Administered To Children Above the Age of 2 By September
Share
Tweet
